Pharma Giant Regeneron to buy 23andme and its customers’ data for $ 256 million

Regeneron pharmaceutical maker Advertise Monday The genetic test company will buy 23andme for $ 256 million after the bankruptcy auction.

Regeneron said it will get the 23ndme genome service and its bank, which includes 15 million genetic personal data as part of the deal. Pharma Giant said it plans to use customer 23ndme data to help detect drugs, and that it “will give priority to privacy, security and moral use of 23andme customer data.”

23andme I applied to protect bankruptcy in March After the data breach Disclosure of private and genetic data from 7 million customers Throughout 2023. The company’s share price also decreased to zero amid consumer interest in the company’s DNA testing groups. The founder of 23andme and CEO Ann Wujiki resigned from the company after the company collapsed.

After submitting it, a federal bankruptcy court was appointed to oversee the sale of 23andme assets, which raised fears that customer data stores. It can be sold to non -moral rivalry countries.

In its statement, Regeneron said that, as the buyer named at the bankruptcy auction, he “intends to guarantee compliance” of the 23ndme policies and laws related to customer data.

The bankruptcy court is scheduled to consider the Regeneron acquisition on June 17. Regeneron said she will not get 23andme’s lemonaid health Business.